In April 2010 in the United Kingdom (UK) a thirteen valent pneumococcal vaccine (PCV13) replaced the seven-valent one (PCV7).
We examined PCV13 impact on childhood pneumonia and empyema admissions.
We found an added benefit of PCV13 over PCV7 on empyema but not pneumonia admissions in infants.